SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas

K. B. Jones, L. Su, H. Jin, C. Lenz, R Randall, T. M. Underhill, T. O. Nielsen, S. Sharma, M. R. Capecchi

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Synovial sarcoma is a deadly malignancy with limited sensitivity to traditional cytotoxic chemotherapy. SS18-SSX fusion oncogene expression characterizes human synovial sarcomas and drives oncogenesis in a mouse model. Elevated expression of BCL2 is considered a consistent feature of the synovial sarcoma expression profile. Our objective was to evaluate the expression of apoptotic pathway members in synovial sarcomas and interrogate the impact of modulating SS18-SSX expression on this pathway. We show in human and murine synovial sarcoma cells that SS18-SSX increases BCL2 expression, but represses other anti-apoptotic genes, including MCL1 and BCL2A1. This repression is achieved by directly suppressing expression via binding through activating transcription factor 2 (ATF2) to the cyclic adenosine monophosphate (AMP) response element (CRE) in the promoters of these genes and recruiting TLE1/Groucho. The suppression of these two anti-apoptotic pathways silences the typical routes by which other tumors evade BH3-domain peptidomimetic pharmacotherapy. We show that mouse and human synovial sarcoma cells are sensitive in vitro to ABT-263, a BH3-peptidomimetic, much more than the other tested cancer cell lines. ABT-263 also enhances the sensitivity of these cells to doxorubicin, a traditional cytotoxic chemotherapy used for synovial sarcoma. We also demonstrate the capacity of ABT-263 to stunt synovial sarcomagenesis in vivo in a genetic mouse model. These data recommend pursuit of BH3-peptidomimetic pharmacotherapy in human synovial sarcomas.

Original languageEnglish (US)
Pages (from-to)2365-2371
Number of pages7
JournalOncogene
Volume32
Issue number18
DOIs
StatePublished - May 2 2013
Externally publishedYes

Fingerprint

Synovial Sarcoma
Apoptosis
Peptidomimetics
Drug Therapy
Oncogene Fusion
Activating Transcription Factor 2
Neoplasms
Genetic Models
Response Elements
Cyclic AMP
Doxorubicin
Genes
Carcinogenesis
Cell Line

Keywords

  • apoptosis
  • chemotherapy
  • mouse model
  • synovial sarcoma
  • targeted therapy

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Jones, K. B., Su, L., Jin, H., Lenz, C., Randall, R., Underhill, T. M., ... Capecchi, M. R. (2013). SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. Oncogene, 32(18), 2365-2371. https://doi.org/10.1038/onc.2012.247

SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. / Jones, K. B.; Su, L.; Jin, H.; Lenz, C.; Randall, R; Underhill, T. M.; Nielsen, T. O.; Sharma, S.; Capecchi, M. R.

In: Oncogene, Vol. 32, No. 18, 02.05.2013, p. 2365-2371.

Research output: Contribution to journalArticle

Jones, KB, Su, L, Jin, H, Lenz, C, Randall, R, Underhill, TM, Nielsen, TO, Sharma, S & Capecchi, MR 2013, 'SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas', Oncogene, vol. 32, no. 18, pp. 2365-2371. https://doi.org/10.1038/onc.2012.247
Jones, K. B. ; Su, L. ; Jin, H. ; Lenz, C. ; Randall, R ; Underhill, T. M. ; Nielsen, T. O. ; Sharma, S. ; Capecchi, M. R. / SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. In: Oncogene. 2013 ; Vol. 32, No. 18. pp. 2365-2371.
@article{0e18c49a416b41518724e8b8a0d2a713,
title = "SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas",
abstract = "Synovial sarcoma is a deadly malignancy with limited sensitivity to traditional cytotoxic chemotherapy. SS18-SSX fusion oncogene expression characterizes human synovial sarcomas and drives oncogenesis in a mouse model. Elevated expression of BCL2 is considered a consistent feature of the synovial sarcoma expression profile. Our objective was to evaluate the expression of apoptotic pathway members in synovial sarcomas and interrogate the impact of modulating SS18-SSX expression on this pathway. We show in human and murine synovial sarcoma cells that SS18-SSX increases BCL2 expression, but represses other anti-apoptotic genes, including MCL1 and BCL2A1. This repression is achieved by directly suppressing expression via binding through activating transcription factor 2 (ATF2) to the cyclic adenosine monophosphate (AMP) response element (CRE) in the promoters of these genes and recruiting TLE1/Groucho. The suppression of these two anti-apoptotic pathways silences the typical routes by which other tumors evade BH3-domain peptidomimetic pharmacotherapy. We show that mouse and human synovial sarcoma cells are sensitive in vitro to ABT-263, a BH3-peptidomimetic, much more than the other tested cancer cell lines. ABT-263 also enhances the sensitivity of these cells to doxorubicin, a traditional cytotoxic chemotherapy used for synovial sarcoma. We also demonstrate the capacity of ABT-263 to stunt synovial sarcomagenesis in vivo in a genetic mouse model. These data recommend pursuit of BH3-peptidomimetic pharmacotherapy in human synovial sarcomas.",
keywords = "apoptosis, chemotherapy, mouse model, synovial sarcoma, targeted therapy",
author = "Jones, {K. B.} and L. Su and H. Jin and C. Lenz and R Randall and Underhill, {T. M.} and Nielsen, {T. O.} and S. Sharma and Capecchi, {M. R.}",
year = "2013",
month = "5",
day = "2",
doi = "10.1038/onc.2012.247",
language = "English (US)",
volume = "32",
pages = "2365--2371",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "18",

}

TY - JOUR

T1 - SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas

AU - Jones, K. B.

AU - Su, L.

AU - Jin, H.

AU - Lenz, C.

AU - Randall, R

AU - Underhill, T. M.

AU - Nielsen, T. O.

AU - Sharma, S.

AU - Capecchi, M. R.

PY - 2013/5/2

Y1 - 2013/5/2

N2 - Synovial sarcoma is a deadly malignancy with limited sensitivity to traditional cytotoxic chemotherapy. SS18-SSX fusion oncogene expression characterizes human synovial sarcomas and drives oncogenesis in a mouse model. Elevated expression of BCL2 is considered a consistent feature of the synovial sarcoma expression profile. Our objective was to evaluate the expression of apoptotic pathway members in synovial sarcomas and interrogate the impact of modulating SS18-SSX expression on this pathway. We show in human and murine synovial sarcoma cells that SS18-SSX increases BCL2 expression, but represses other anti-apoptotic genes, including MCL1 and BCL2A1. This repression is achieved by directly suppressing expression via binding through activating transcription factor 2 (ATF2) to the cyclic adenosine monophosphate (AMP) response element (CRE) in the promoters of these genes and recruiting TLE1/Groucho. The suppression of these two anti-apoptotic pathways silences the typical routes by which other tumors evade BH3-domain peptidomimetic pharmacotherapy. We show that mouse and human synovial sarcoma cells are sensitive in vitro to ABT-263, a BH3-peptidomimetic, much more than the other tested cancer cell lines. ABT-263 also enhances the sensitivity of these cells to doxorubicin, a traditional cytotoxic chemotherapy used for synovial sarcoma. We also demonstrate the capacity of ABT-263 to stunt synovial sarcomagenesis in vivo in a genetic mouse model. These data recommend pursuit of BH3-peptidomimetic pharmacotherapy in human synovial sarcomas.

AB - Synovial sarcoma is a deadly malignancy with limited sensitivity to traditional cytotoxic chemotherapy. SS18-SSX fusion oncogene expression characterizes human synovial sarcomas and drives oncogenesis in a mouse model. Elevated expression of BCL2 is considered a consistent feature of the synovial sarcoma expression profile. Our objective was to evaluate the expression of apoptotic pathway members in synovial sarcomas and interrogate the impact of modulating SS18-SSX expression on this pathway. We show in human and murine synovial sarcoma cells that SS18-SSX increases BCL2 expression, but represses other anti-apoptotic genes, including MCL1 and BCL2A1. This repression is achieved by directly suppressing expression via binding through activating transcription factor 2 (ATF2) to the cyclic adenosine monophosphate (AMP) response element (CRE) in the promoters of these genes and recruiting TLE1/Groucho. The suppression of these two anti-apoptotic pathways silences the typical routes by which other tumors evade BH3-domain peptidomimetic pharmacotherapy. We show that mouse and human synovial sarcoma cells are sensitive in vitro to ABT-263, a BH3-peptidomimetic, much more than the other tested cancer cell lines. ABT-263 also enhances the sensitivity of these cells to doxorubicin, a traditional cytotoxic chemotherapy used for synovial sarcoma. We also demonstrate the capacity of ABT-263 to stunt synovial sarcomagenesis in vivo in a genetic mouse model. These data recommend pursuit of BH3-peptidomimetic pharmacotherapy in human synovial sarcomas.

KW - apoptosis

KW - chemotherapy

KW - mouse model

KW - synovial sarcoma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84877584164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877584164&partnerID=8YFLogxK

U2 - 10.1038/onc.2012.247

DO - 10.1038/onc.2012.247

M3 - Article

VL - 32

SP - 2365

EP - 2371

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 18

ER -